Form 4: Solid Biosciences Director Lynne Marie Sullivan Reports Stock Option Grant

Director Lynne Marie Sullivan reports the acquisition of stock options in Solid Biosciences Inc.

Summary

• Lynne Marie Sullivan, a director of Solid Biosciences Inc., filed a Form 4 on June 13, 2024, reporting a transaction.
• On June 11, 2024, Sullivan was granted a stock option to purchase 34,400 shares of Solid Biosciences Inc. common stock at an exercise price of $7.51 per share.
• The option vests in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date.
• The option will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.
• The option expires on June 11, 2034.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing, indicating a neutral sentiment. The stock option grant is a positive incentive for the director, but it doesn't significantly alter the company's overall outlook.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders by incentivizing them to increase the company's stock value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• Companies like Sarepta Therapeutics and BioMarin Pharmaceutical also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially leading to decisions that benefit the company's long-term value.

Key Dates